ARTNet Podcast

ARTNet Podcast

Download on the App Store

ARTNet Podcast episodes

  • Resistance Before Treatment Begins: Why Some Tumors Are Already Primed to Survive

    Featuring

    Vlad Sandulache

    Associate Professor, Baylor College of Medicine

    MPI, ARTNet H-CARR U 54 Center

    Dr. Sandulache is a clinician-scientist studying head and neck cancer, with a focus on treatment resistance, tumor metabolism, oxidative stress, and the biological mechanisms that determine how tumors respond to radiation and chemotherapy.

    Hosted by

    David Goodrich

    Professor, Roswell Park Comprehensive Cancer Center

    ARTNet Coordinating and Data Management Center

    Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.

    Episode Summary

    The conversation explores how resistance to cancer therapy may begin long before treatment starts. Dr. Sandulache discusses how head and neck tumors can be shaped by selective pressures,including metabolism, oxidative stress, environmental exposures, and immune interactions,that may precondition cancer cells to withstand radiation and chemotherapy. This perspective challenges the traditional distinction between innate and acquired resistance, suggesting that tumor evolution before treatment can profoundly influence therapeutic response.

    The discussion highlights oxidative stress as a key driver of this preconditioning and explores the NRF2 pathway as an important mechanism through which tumor cells build antioxidant defenses and become resistant to therapies such as cisplatin and radiation. Dr. Sandulache also discusses opportunities to identify resistant tumors before treatment using transcriptional biomarkers, tumor biopsies, circulating DNA, and metabolic imaging, potentially allowing treatment to be tailored according to a tumor’s resistance profile.

    The episode also emphasizes the value of team science within ARTNet, where investigators studying different cancers, therapies, and resistance mechanisms can bring complementary expertise to shared questions.

    Key Takeaways

    • Treatment resistance may be shaped long before cancer therapy begins
    • Metabolic and environmental oxidative stress can precondition tumors to withstand radiation and chemotherapy
    • The distinction between innate and acquired resistance may be less clear than traditionally assumed
    • NRF2-driven antioxidant defenses may play an important role in resistance to oxidative stress-based therapies
    • Transcriptional biomarkers and emerging technologies may help identify resistant tumors before treatment
    • Understanding pretreatment tumor biology could enable treatment escalation for resistant disease and de-escalation for sensitive disease
    • Cross-disciplinary collaboration within ARTNet helps reveal resistance mechanisms that may apply across different cancer types
    44 min
  • Why Cancer Fights Back: A Conversation with Jeffrey Tyner

    Featuring

    Jeffrey Tyner

    Professor, Oregon Health & Science University

    Principle Investigator, ARTNet AML U54 Center

    Dr. Tyner is a leading researcher in cancer biology and therapeutic resistance, with a focus on acute myeloid leukemia (AML), functional precision oncology, and mechanisms of acquired resistance to targeted therapies.

    Hosted by

    David Goodrich

    Professor, Roswell Park Comprehensive Cancer Center

    ARTNet Coordinating and Data Management Center

    Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.

    Episode Summary

    The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how resistance trajectories evolve over time.

    The discussion also highlights the importance of identifying the optimal window for intervention and the growing role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology and translational cancer research.

    Key Takeaways

    • Acquired resistance is a dynamic and evolving process in cancer therapy
    • Cell state plasticity plays a central role in therapeutic resistance
    • Resistance mechanisms can differ across patients and tumor contexts
    • Understanding resistance trajectories may reveal new therapeutic opportunities
    • Collaborative research and data sharing are essential for advancing precision oncology

    Chapters

    • 00:00 Introduction to ARTNet Consortium
    • 05:15 From Targeted Therapy to Tumor Complexity
    • 10:15 Understanding Acquired Resistance and Tumor Evolution
    • 19:50 Cell State Plasticity and Therapeutic Resistance
    • 24:05 Resistance Trajectories and Future Treatment Strategies
    • 29:00 The Future of Precision Oncology and the Role of ARTNet
    36 min

About ARTNet Podcast

From the publisher's feed

ARTNet Podcast is the official podcast of the National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). The series features conversations with leading cancer…